Emma specializes in extractables and leachables (E&L) studies with more than 40 peer reviewed publications. She has more than 11 years of research experience in the scientific community, successfully moving from academia to industry.
Emma earned a Ph.D. in Neuroscience from Indiana University and launched her industry career as an Analytical Chemist at ÌÇÐÄlogoÃ×·ÆÍÃAnn Arbor. Leveraging previous LC-MS/MS expertise, she expanded her toolkit to include other mass spectrometry techniques, contributing to Extractables and Leachables (E&L) studies. In just a few years, Emma transitioned to leadership and was promoted to Manager of Advanced Analytics.
Working to ensure medicines are safe and accessible, the Advanced Analytics department specializes in E&L and mass spectrometry methods under both R&D and cGMP quality systems. The group runs complete programs, seeing a study through from early development, to validation, and finally to stability sample testing. Her team has over 99% on-time delivery, contributing to FDA approvals for life-saving drugs.
Emma is based at ÌÇÐÄlogoÃ×·ÆÍÃAnn Arbor, but works closely with all of the Life Sciences labs across the Americas.
With years of proven success in developing, validating, and releasing OTC products with complex and challenging active ingredients and matrices, including colloidal oatmeal, ÌÇÐÄlogoÃ×·ÆÍÃis the partner of choice for leading OTC product developers and manufacturers.
Learn more about our development of OTC colloidal oatmeal in the article linked below.
Read More